Transition to lanadelumab‐flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report

Abstract

Abstract Non‐SERPING1 gene variant hereditary angioedema patients often need to take progesterone, attenuated androgens, and antifibrinolytics to control symptoms. These drugs may need to be tapered to extinction or reduced as lanadelumab‐flyo reaches maximum concentration.

Keywords

• hereditary angioedema
• lanadelumab‐flyo
• SYTL2